Objective: The aim of this study was to use routinely collected electronic medicines administration (eMAR) data in residential aged care (RAC) to investigate the quality use of medicines. Design: A cross-sectional analysis of eMAR data. Setting: 71 RAC facilities in New South Wales and the Australian Capital Territory, Australia. Participants: Permanent residents living in a participating facility on 1 October 2015. Intervention: None. Main Outcome Measures: Variation in polypharmacy (≥5 medications), hyper-polypharmacy (≥10 medications) and antipsychotic use across facilities was examined using funnel plot analysis. Results: The study dataset included 4775 long-term residents. The mean resident age was 85.3 years and 70.6% of residents were female. The median facility size was 60 residents and 74.3% were in metropolitan locations. 84.3% of residents had polypharmacy, 41.2% hyper-polypharmacy and 21.0% were using an antipsychotic. The extent of polypharmacy (69.75-100% of residents), hyper-polypharmacy (38.81-76.19%) and use of antipsychotic medicines (0-75.6%) varied considerably across the 71 facilities. Conclusions: Using eMAR data we found substantial variation in polypharmacy, hyperpolypharmacy and antipsychotic medicine use across 71 RAC facilities. Further investigation into the policies and practices of facilities performing above or below expected levels is warranted to understand variation and drive quality improvement.
Introduction
Information and communication technology (ICT) is changing Australian healthcare. Digital health systems including electronic health records, clinical information systems and electronic medication administration systems are being implemented across a range of healthcare settings [1] . The residential aged care (RAC) sector has traditionally been slow to adopt ICT [2] . However, over the past 10-15 years there has been growth in the uptake of ICT in RAC [2] . While the primary goal of these systems is to support the provision of healthcare [3] , the data captured by these systems also has potential to inform practice and drive quality improvement.
Medicine use in RAC facilities continues to raise quality and safety concerns [4] . Frailty, immunosenescence, medical complexity and high levels of medication use all increase the risk of medicationrelated harm for long-term RAC residents [5] . International studies indicate that, half of all RAC residents use a potentially inappropriate medicine [6] , 91% use five or more medications concomitantly (polypharmacy) [7] and 40% are using an antipsychotic medication [8] . All of which contribute to a high risk of medication-related harm among this already vulnerable population [6] [7] [8] . High use of multiple medicines concomitantly, as well as use of potentially inappropriate medicines such as antipsychotics, have been associated with poorer residents outcomes [4, 9] .
Currently, monitoring the quality of medicine use in RAC requires manual extraction of information from paper-based medical records and medication administration charts [10] . Such manual processes are time and resource intensive. As such they are generally performed on a small sample or within specific sub-populations [10, 11] , substantially limiting their value in monitoring medicine use over time. With ICT systems being implemented in RAC, there are new opportunities to obtain extensive ongoing data in a timely manner. Electronic medicine administration record systems (eMARs) collect a wide range of data that could be used to explore the quality use of medicines across large RAC populations, allowing variation to be identified across different contexts such as geographical location or level of care provided. While some variation in medicine use, reflecting personal needs and preferences, is expected, variation may also signal inappropriate or unnecessary care [12] .
The aim of this study was to use routinely collected eMAR data to explore variation in medicine use across 71 RAC facilities. We focused on rates of polypharmacy, hyper-polypharmacy (≥10 concurrent medicines) and antipsychotic use as potential indicators associated with quality use of medicines in RAC.
Methods

Setting and data source
Medicine administration and resident demographic data were extracted from all Uniting RAC facilities located in New South Wales (NSW) and the Australian Capital Territory (ACT). NSW and the ACT is home to one third of the total Australian population, approximately 8 308,400 inhabitants. Uniting is the largest provider of aged and community care services in Australia providing 7% of NSW and ACT RAC beds [13] . The profile of Uniting residents does not different significantly from the national profile of RAC residents [14] . All Uniting facilities use an electronic clinical information system (iCareHealth) that includes an electronic medication administration record (eMAR) module.
De-identified demographic and medicine use data for permanent residents living in a NSW or ACT Uniting facility on 1 October 2015 were extracted from the relevant clinical information systems. We linked eMAR data with resident demographic data via a unique non-identifiable resident-number. Short-stay respite care residents were excluded from the dataset. Short-stay residents are communitydwelling individuals who receive temporary respite care for a maximum of 2 weeks at a RAC facility. As such their medication use is not likely to be influenced by, or representative of, the care provided in the facility and for this reason they were excluded from the analysis. Facilities with less than five permanent residents in the dataset (three facilities) were also excluded as they contain an inadequate number of residents for considering variation in care. After shortstay residents and the three facilities with less than 5 permanent residents were excluded, the final dataset included 71 facilities and 4475 residents.
Medicines
All prescription, non-prescription and complementary medicines administered to facility residents are recorded in the eMAR. Medication name, strength, dose, and date and time of administration are recorded for each administration episode allowing a complete medication profile to be developed for each resident, based on what is actually prescribed and administered. Demographic data for all residents including age, sex, facility postcode, date of admission, date of departure, facility identifier and level of care were extracted from the clinical information systems. Within the system, the level of care is classified as high for those residents requiring 24 h nursing care and low for residents who are more independent.
Medicines were mapped to the World Health Organisation Anatomical Therapeutic Chemical (ATC) Classification system. The ATC system is a hierarchical classification that assigns medicines into groups according to the organ or system on which they act and the therapeutic, pharmacological and chemical properties [15] . Each medicine receives a seven-digit code of which the first letter represents the body system the medicine works on (ATC Level 1), the first three digits identify the therapeutic subgroup (ATC Level 2), the first four digits the pharmacological subgroup (ATC Level 3), five digits the chemical subgroup and all seven digits the individual generic medicine.
Geographical remoteness as per the Australian Statistical Geography Standard (ASGS) remoteness structure (ARIA 2011) was mapped using facility postcode [16] . The ASGS classifies the remoteness of areas as major cities, inner regional, outer regional, remote and very remote.
Analysis
A medication profile was created for each resident from the eMAR data. The point prevalence of polypharmacy, hyper-polypharmacy and antipsychotic use was calculated over a 24-h period (1 October 2015) . Polypharmacy was defined as the concurrent use of five of more medicines (including prescription, non-prescription and complementary) [17] and hyper-polypharmacy the use of 10 or more medicines [18] . Confidence intervals were calculated using Wilson score interval [19] .
To demonstrate the value of the eMAR data for monitoring quality use of medicines across different contexts we compared the rates of polypharmacy, hyper-polypharmacy and antipsychotic use by care level, facility and geographical remoteness using Pearson's χ 2 . Funnel plot analysis allows visual comparison of data derived from multiple healthcare units [20] by plotting the observed rate for each outcome, in this study, medication use, against the population size, in this case the facility size. Control limits were set at 95% and 99.8%, approximating two and three standard deviations from the mean [21] . Funnel shaped control limits represent expected variation in outcomes if the only variation present is random and facilities which fall outside the control limits represent those with higher or lower than expected levels of medicine use. Thus, funnel plot analysis provides a mechanism for comparing variation between sites and identifying potentially high and poor performers, while accounting for the increased variability expected from smaller facilities. Funnel plot analysis on the proportion of users per facility, was conducted using the funnelcompar package in Stata for a binomial distribution as per Spiegelhalter [22] . Fishers exact test was used to test for associations between facility outliers (facilities lying outside the 95% control limits) and level of care/geographical remoteness.
Data were managed and analysed using Microsoft Access 2013 software (Microsoft Corporation, Redmond, WA, USA), SAS 9.4 (SSA Institute Inc, Cary, NC, USA) and Stata 15 (StataCorp. 2018. College Station, TX: StataCorp LP).
Ethical approval
The study was approved by Macquarie University Human Research Ethics committee (5201401031).
Results
Resident and facility characteristics
Study residents had a similar age and sex distribution to those in the general Australian RAC population [23] ( Table 1 ). The average length of stay for residents in the study dataset was longer than the national average, however the national population also includes short-stay respite residents, which may account for the differences in average length of stay. The majority of residents in the study were receiving high-level care (N = 3280, 68.7%).
The median facility size was 60 residents (inter-quartile range (IQR): 40-89 residents). Almost three quarters (N = 55, 74.3%) of facilities were located in a major city; 23.0% (N = 16) were located in an inner regional area and 2.7% (N = 2) in an outer regional area. No facilities were located in remote or very remote locations.
There was no difference in facility size by geographical location (P = 0.71). Most facilities (N = 57, 80.3%) provided high-level care to over 50% of residents. Only 14 facilities (19.7%) provided low-level care to the majority of residents.
Medicine use
Medicine use within the population was high. The majority of residents received at least one medication during the 24-h study period ( Table 1 ). The most frequently administered medicine was paracetamol, received by almost three quarters of residents. Over 80% of residents (82.3% (95% CI: 81.3-83.4)) received a medicine that acted on the nervous system (ATC N); 21.3% (95% CI: 20.2-22.5) used an opioid or opioid-containing combination. Benzodiazepines and benzodiazepine-like medications (ATC N05A or N05B), were used by 15.7% (95% CI: 14.7-16.7) of residents. Just under half of study residents (41.5%, 95% CI: 40.1-42.9) used an antidepressant medicine (ATC N06A). Use of occasional or 'as needed' medicines was relatively low (6.3% (95% CI: 5.7-7.0 of residents)). Opioids were the most commonly used occasional medicine accounting for 26.0% (95% CI 24.8-27.3) of 'as needed' medicines.
Of all medicines administered within the 24-h, 6.7% were complementary medicines, with the majority of residents 83.3% (82.3-84.3) using one or more complementary medicines.
Polypharmacy
Eighty-four percent of all residents had polypharmacy (≥5 medicines) ( Table 1) . At the resident level, there was no association between level of care (P = 0.14) or geographical remoteness (P = 0.13) and polypharmacy. The proportion of residents with polypharmacy per facility ranged from 69.8-100%. Looking at the funnel plot analysis (Fig. 1) if the variation in polypharmacy between the facilities was only random it would be expected that 2.5% of facilities (1-2 facilities) would lie outside each of the upper and lower 95% control limits. Our dataset showed higher than expected variation in polypharmacy with 7 (9.5%) of facilities having higher than expected (i.e. lying outside the upper 95% control limits) and nine facilities with lower than expected (i.e. below the lower 95% control limits) rates of polypharmacy. Facility outliers, with higher or lower than expected levels of polypharmacy were not associated with the level of care provided by the facility (P = 0.626) or geographical remoteness (P = 0.790).
Hyper-polypharmacy
Within our dataset, 41.2% of residents had hyper-polypharmacy (≥10 medicines), At the resident level, there was no association between care level (P = 0.33) or geographical remoteness (P = 0.97) and hyper-polypharmacy.
The proportion of residents with hyper-polypharmacy ranged from 38.8% to 76.2%. The funnel plot for hyper-polypharmacy shows wider variation compared with the polypharmacy plots (Fig. 2) . Eight facilities (10.8%,) had higher than expected levels of hyper-polypharmacy and 10 facilities (14.1%) had lower than expected levels? Facility outliers, with higher or lower than expected levels of hyper-polypharmacy, were not associated with the level of care (P = 0.34) provided by those facilities or by geographic location (P = 0.38).
Antipsychotic use
Around one-fifth of residents (21.0%, 95% CI 24.8-27.3) were using an antipsychotic (Table 1) . At the resident level antipsychotic use varied by care level, with residents receiving a high care level more likely to receive an antipsychotic than those with a lower care level (22.8% vs. 17.2%, P < 0.001) but not by geographical remoteness (P = 0.34) (Fig. 3) .
There was considerable variation between facilities in the proportion of residents using an antipsychotic (0-75.6%). Eleven facilities (14.9%) had higher than expected levels of antipsychotic use while eight facilities (11.3%) had antipsychotic use that was lower than expected. The facility with the highest rate of antipsychotic use (75.6%) specialised in RAC for individuals with mental health issues. Facility outliers, with higher or lower than expected antipsychotic utilisation, were not explained by level of care (P = 0.12) provided by those facilities or by geographic location (P = 0.54). 
Discussion
Using eMAR data we found considerable variation in polypharmacy, hyper-polypharmacy and antipsychotic medicine use across the 71 facilities in our study. This variation was not associated with facility care level, or geographical remoteness, suggesting further investigations into the policies and practices of facilities performing above or below expected levels is warranted. Our findings regarding high levels of polypharmacy mirror those from other studies. A large Australian study reported similar rates of polypharmacy among RAC residents on admission to hospital [24] . In addition to high levels of polypharmacy and hyper-polypharmacy among residents, we identified considerable variation in the levels of polypharmacy and hyper-polypharmacy between facilities. Almost one in ten facilities had levels of polypharmacy and 11% of facilities had levels of hyper-polypharmacy that were higher than expected lying outside the upper 95% control limit. Such variation suggests the need for further investigation and targeted medicine-related quality improvement interventions such as de-prescribing to reduce unnecessary medicines and standardise care [24] . While polypharmacy is not necessarily a direct measure of quality use of medicines [25] , it has been associated with increased falls, confusion and functional decline [4, 18] . The setting of targets for reducing harmful or unnecessary medicines was recently proposed as a useful strategy to improve quality use of medicines to optimise ageing [26] . Yet, a major challenge identified was the difficulty in monitoring progress and effects. The use of electronic medicines data can clearly facilitate progress towards this goal.
Wide variation in the proportion of residents in our dataset using an antipsychotic medication at different facilities was not explained by facility level of care or remoteness. Internationally, there is concern regarding the use of antipsychotic medicines for behaviour management in RAC [9, 27] . Antipsychotics are widely used for the management of behavioural and psychological symptoms of dementia, despite limited evidence of their effectiveness [27] . Like polypharmacy, use of antipsychotics in RAC has been shown to increase the risk of falls, hospitalisation and mortality [28] . Across our dataset, the prevalence of antipsychotic use was 21% which is consistent with that previously reported in Australian RAC facilities [29] . However looking at the proportion of antipsychotic users per facility, we found low use in some facilities and high use in others. Looking at variation graphically using funnel plots we found that almost 15% of facilities had antipsychotic utilisation that was significantly higher than the remainder of the dataset. In interpreting any variation consideration should be given to the context in which the care is being provided. Outliers may be explained with the limited additional investigation. For example, we identified one extreme outlier was a facility specialising in the care of individuals with mental health issues, and thus a greater use of antipsychotics would be expected.
We found no association in our study between variation in polypharmacy, hyper-polypharmacy and antipsychotic use and facility care level. A small study looking at the level of care in RAC and medication use by Wayne et al. [30] conducted in 1992, looked at medication use among 81 RAC residents over a 3-month period. Consistent with our findings, no association between medication use and care level was found [30] . Strategies to optimise medicine use have tended to focus on RAC residents with high-level healthcare needs [31] , yet our results show, with the exception of antipsychotic use, there was little variation in the quantity of medicine use between those with higher and lower care needs.
Quality improvement can be considered in a step-wise approach [32] . The Australian Commission on Safety and Quality in Healthcare has identified four strategies for reducing healthcare variation: policies supporting optimal care, engagement of clinicians, shared decision-making between healthcare providers and patients, and increased research into factors and outcomes associated with variation [33] . Reducing inappropriate variation in medicine use is the first step towards improving quality. Identifying facilities with rates of polypharmacy or antipsychotic use substantially higher than their peers, i.e. those outside the upper 95% and 99.8% control limits, may allow targeting of investigations, and strategies to address any inappropriate use. Understanding and sharing the policies and practices from performance leading sites, such as those lying below the lower 99.8% control limit may further contribute to understanding high performing facilities and thus, driving quality improvement. Feedback and sharing of performance data has been used to be effective in improving care within the acute care setting [34] . Currently, RAC facilities have access to very limited comparative data against which to examine their practice. Our study demonstrates the potential value of electronic medication data to allow facilities to target their quality improvement activities and to monitor changes over time.
General practitioners are largely responsible for the quality and management of prescribing for aged care residents, but they are reliant upon a complex medicine co-ordination process shared with RAC facility staff and community pharmacists [35, 36] . RAC facilities are responsible for administering medications safety, but also for ensuring the overall quality of services provided to residents. eMAR systems provide the possibility of timely medicine profiles of residents under their care. As such these data should present as a new opportunity to engage in meaningful discussions with GPs to address potential areas of concern regarding medicine use and reviews.
A limitation of our study is that information about indication or comorbidities is not included in the eMAR data. Thus, we were unable to control for facilities with higher resident acuity or a higher proportion of residents with psychotic disorders who are likely to have higher levels of polypharmacy and/or antipsychotic utilisation. Future development of RAC clinical information systems to allow systematic collection of comorbidity and other relevant clinical data would further increase the potential for routinely collected electronic data to be used in quality improvement.
Identification of quality indicators for RAC facilities has been a focus internationally for both Government and aged care providers [37] . However, gaining consensus on meaningful indicators, which can be accurately measured and monitored in a timely fashion, has been elusive. Improvements in medicine management is one of the central interventions which can have substantial impacts on residents' quality of life and thus should be targeted as a priority. Yet to date, medicine management has not featured as a possible national indicator due to the challenges in gaining access to monitoring data. The increased adoption of electronic clinical information systems by RAC facilities is a potential 'game-changer' here, allowing timely access to resident and service data with the potential to examine trends over time.
